{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:54:06Z","timestamp":1793332446924,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"17","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Bard Peripheral Vascular, Inc."},{"DOI":"10.13039\/100016242","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016242","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cook Research Incorporated"},{"DOI":"10.13039\/100004374","name":"Medtronic, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Philips Medical"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Femoropopliteal artery disease is associated with high rates of post-revascularization restenosis. Drug-coated devices (DCD), including drug-coated balloons (DCBs) and drug-eluting stents (DES), have demonstrated efficacy in reducing restenosis rates compared to non-drug-coated devices (NDCDs). However, concerns about potential long-term mortality risks have led to regulatory scrutiny. This study represents the final report from the Safety Assessment of Femoropopliteal Endovascular Treatment with Paclitaxel-Coated Devices (SAFE-PAD) study, a pre-specified analysis designed with the US Food and Drug Administration to evaluate the long-term mortality associated with femoropopliteal DCD use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>SAFE-PAD was a retrospective cohort study of 168 553 Medicare fee-for-service beneficiaries (\u226566 years) who underwent femoropopliteal artery revascularization between 2015 and 2018. Device exposure (DCDs vs. NDCDs) was identified using Medicare claims data. The primary outcome was all-cause mortality, assessed between treatment groups using inverse probability treatment weighting. Secondary outcomes included all-cause hospitalizations, repeat revascularization, major amputation, and cardiovascular medication use. Sensitivity analyses included instrumental variable methods, falsification endpoints, and simulation of hypothetical unmeasured confounders. Subgroup analyses examined outcomes in inpatient vs outpatient settings, in younger\/low-risk populations, and in high-risk chronic limb-threatening ischaemia patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At a median follow-up of 4.3 years (maximum: 9.0 years), DCD use was not associated with increased mortality (adjusted hazard ratio: 0.98; 95% confidence interval: 0.97, 0.99), meeting the pre-specified 5% non-inferiority relative margin. Sensitivity analyses supported the validity of the primary result. Secondary outcomes showed similar hospitalization and amputation rates between groups but an increase in repeat revascularization with DCDs. Subgroup analyses confirmed safety findings across high\/low-risk subgroups and across clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this final report from the SAFE-PAD study, there was no evidence of long-term mortality risk associated with DCDs used for femoropopliteal revascularization. The SAFE-PAD study helped inform the reversal of regulatory warnings against routine DCD use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf721","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:45:19Z","timestamp":1756899919000},"page":"2093-2103","source":"Crossref","is-referenced-by-count":7,"title":["Drug-coated vs non-drug-coated devices for femoropopliteal artery interventions: long-term outcomes of the SAFE-PAD study"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-3927","authenticated-orcid":false,"given":"Joseph M","family":"Kim","sequence":"first","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , 375 Longwood Ave, 4th Floor, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0564-4468","authenticated-orcid":false,"given":"Robert W","family":"Yeh","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , 375 Longwood Ave, 4th Floor, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , 375 Longwood Ave, 4th Floor, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3861-3163","authenticated-orcid":false,"given":"Eric A","family":"Secemsky","sequence":"additional","affiliation":[{"name":"Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , 375 Longwood Ave, 4th Floor, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2026050419565972900_ehaf721-B1","doi-asserted-by":"publisher","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"2026050419565972900_ehaf721-B2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa0706356","article-title":"Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg","volume":"358","author":"Tepe","year":"2008","journal-title":"N Engl J Med"},{"key":"2026050419565972900_ehaf721-B3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.114.011004","article-title":"Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial","volume":"131","author":"Tepe","year":"2015","journal-title":"Circulation"},{"key":"2026050419565972900_ehaf721-B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1526602814564383","article-title":"Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial","volume":"22","author":"Scheinert","year":"2015","journal-title":"J Endovasc Ther"},{"key":"2026050419565972900_ehaf721-B5","doi-asserted-by":"publisher","first-page":"e005891","DOI":"10.1161\/CIRCINTERVENTIONS.117.005891","article-title":"Treatment effect of drug-coated Balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial","volume":"11","author":"Schneider","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"2026050419565972900_ehaf721-B6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ejvs.2017.07.018","article-title":"Editor's choice\u20142017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)","volume":"55","author":"Aboyans","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2026050419565972900_ehaf721-B7","doi-asserted-by":"publisher","first-page":"e007702","DOI":"10.1161\/CIRCINTERVENTIONS.118.007702","article-title":"Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions","volume":"12","author":"Laird","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"2026050419565972900_ehaf721-B8","doi-asserted-by":"publisher","first-page":"e011245","DOI":"10.1161\/JAHA.118.011245","article-title":"Risk of death following application of paclitaxel-coated Balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Katsanos","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026050419565972900_ehaf721-B9","author":"U.S. Food Drug Administration"},{"key":"2026050419565972900_ehaf721-B10","doi-asserted-by":"publisher","first-page":"e007040","DOI":"10.1161\/CIRCOUTCOMES.120.007040","article-title":"Rationale and design of the SAFE-PAD study","volume":"14","author":"Secemsky","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026050419565972900_ehaf721-B11"},{"key":"2026050419565972900_ehaf721-B12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jamainternmed.2021.2738","article-title":"Longitudinal assessment of safety of femoropopliteal endovascular treatment with paclitaxel-coated devices among medicare beneficiaries: the SAFE-PAD study","volume":"181","author":"Secemsky","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2026050419565972900_ehaf721-B13","author":"Jarosek"},{"key":"2026050419565972900_ehaf721-B14","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/j.jacc.2013.07.036","article-title":"Comparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of \u201cFalsification Hypotheses\u201d in observational studies of comparative effectiveness","volume":"62","author":"Wimmer","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026050419565972900_ehaf721-B15","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Communications in Statistics\u2014Simulation and Computation"},{"key":"2026050419565972900_ehaf721-B16","volume-title":"An Introduction to the Bootstrap","author":"Tibshirani","year":"1994","edition":"1st ed"},{"key":"2026050419565972900_ehaf721-B17","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.jcin.2016.09.020","article-title":"Use and effectiveness of bivalirudin versus unfractionated heparin for percutaneous coronary intervention among patients with ST-segment elevation myocardial infarction in the United States","volume":"9","author":"Secemsky","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"2026050419565972900_ehaf721-B18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1001\/jamacardio.2018.4472","article-title":"Association of physician variation in use of manual aspiration thrombectomy with outcomes following primary percutaneous coronary intervention for ST-elevation myocardial infarction: the National Cardiovascular Data Registry CathPCI Registry","volume":"4","author":"Secemsky","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026050419565972900_ehaf721-B19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1001\/jamacardio.2019.0325","article-title":"Association of survival with femoropopliteal artery revascularization with drug-coated devices","volume":"4","author":"Secemsky","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026050419565972900_ehaf721-B20","doi-asserted-by":"publisher","first-page":"e012074","DOI":"10.1161\/CIRCINTERVENTIONS.122.012074","article-title":"Update from the longitudinal assessment of safety of femoropopliteal endovascular treatment with paclitaxel-coated devices among medicare beneficiaries: the SAFE-PAD study","volume":"15","author":"Secemsky","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"2026050419565972900_ehaf721-B21","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/j.jacc.2019.02.020","article-title":"Drug-eluting stent implantation and long-term survival following peripheral artery revascularization","volume":"73","author":"Secemsky","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026050419565972900_ehaf721-B22","author":"U.S. Food and Drug Administration"},{"key":"2026050419565972900_ehaf721-B23","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1056\/NEJMoa2005206","article-title":"Mortality with paclitaxel-coated devices in peripheral artery disease","volume":"383","author":"Nordanstig","year":"2020","journal-title":"N Engl J Med"},{"key":"2026050419565972900_ehaf721-B24","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/S0140-6736(23)02189-X","article-title":"Mortality in randomised controlled trials using paclitaxel-coated devices for femoropopliteal interventional procedures: an updated patient-level meta-analysis","volume":"402","author":"Parikh","year":"2023","journal-title":"Lancet"},{"key":"2026050419565972900_ehaf721-B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01585-5","article-title":"Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial","author":"Falkenberg","year":"2025","journal-title":"The Lancet"},{"key":"2026050419565972900_ehaf721-B26","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)01584-3","article-title":"Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2): a multicentre, participant-masked, registry-based, randomised controlled trial.","author":"Nordanstig","year":"2025","journal-title":"Lancet (London, England)"},{"key":"2026050419565972900_ehaf721-B27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jacc.2024.10.102","article-title":"Dynamic trends and practice patterns in femoropopliteal revascularization from 2016 through 2023","volume":"85","author":"Kim","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026050419565972900_ehaf721-B28","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jcin.2020.03.049","article-title":"Validation of administrative claims to ascertain outcomes in pivotal trials of transcatheter aortic valve replacement","volume":"13","author":"Butala","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2026050419565972900_ehaf721-B29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.123.064645","article-title":"Bringing the credibility revolution to observational research in cardiology","volume":"148","author":"Yeh","year":"2023","journal-title":"Circulation"},{"key":"2026050419565972900_ehaf721-B30"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/17\/2093\/64382016\/ehaf721.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/17\/2093\/64382016\/ehaf721.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:57:10Z","timestamp":1777939030000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/17\/2093\/8263728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":30,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9,25]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf721","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,1]]},"published":{"date-parts":[[2025,9,25]]}}}